These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 36729612)

  • 1. Does PARP Inhibition Sensitize Chondrosarcoma Cell Lines to Chemotherapy or Radiotherapy? Results From a Three-dimensional Spheroid Cell Model.
    Palubeckaitė I; Venneker S; van den Akker BEWM; Briaire-de Bruijn IH; Boveé JVMG
    Clin Orthop Relat Res; 2023 Mar; 481(3):608-619. PubMed ID: 36729612
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibition of PARP Sensitizes Chondrosarcoma Cell Lines to Chemo- and Radiotherapy Irrespective of the
    Venneker S; Kruisselbrink AB; Briaire-de Bruijn IH; de Jong Y; van Wijnen AJ; Danen EHJ; Bovée JVMG
    Cancers (Basel); 2019 Dec; 11(12):. PubMed ID: 31810230
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Selection of Effective Therapies Using Three-Dimensional
    Palubeckaitė I; Venneker S; Briaire-de Bruijn IH; van den Akker BE; Krol AD; Gelderblom H; Bovée JVMG
    Front Mol Biosci; 2020; 7():566291. PubMed ID: 33425984
    [No Abstract]   [Full Text] [Related]  

  • 4. CORR Insights®: Does PARP Inhibition Sensitize Chondrosarcoma Cell Lines to Chemotherapy or Radiotherapy? Results From a Three-dimensional Spheroid Cell Model.
    Levin AS
    Clin Orthop Relat Res; 2023 Mar; 481(3):620-622. PubMed ID: 36638387
    [No Abstract]   [Full Text] [Related]  

  • 5. Synergistic activity of PARP inhibition by talazoparib (BMN 673) with temozolomide in pediatric cancer models in the pediatric preclinical testing program.
    Smith MA; Reynolds CP; Kang MH; Kolb EA; Gorlick R; Carol H; Lock RB; Keir ST; Maris JM; Billups CA; Lyalin D; Kurmasheva RT; Houghton PJ
    Clin Cancer Res; 2015 Feb; 21(4):819-32. PubMed ID: 25500058
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Osteosarcoma cells with genetic signatures of BRCAness are susceptible to the PARP inhibitor talazoparib alone or in combination with chemotherapeutics.
    Engert F; Kovac M; Baumhoer D; Nathrath M; Fulda S
    Oncotarget; 2017 Jul; 8(30):48794-48806. PubMed ID: 27447864
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Do Patient-derived Spheroid Culture Models Have Relevance in Chondrosarcoma Research?
    Ma R; Mandell J; Lu F; Heim T; Schoedel K; Duensing A; Watters RJ; Weiss KR
    Clin Orthop Relat Res; 2021 Mar; 479(3):477-490. PubMed ID: 32469486
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PARP Inhibitor Activity Correlates with SLFN11 Expression and Demonstrates Synergy with Temozolomide in Small Cell Lung Cancer.
    Lok BH; Gardner EE; Schneeberger VE; Ni A; Desmeules P; Rekhtman N; de Stanchina E; Teicher BA; Riaz N; Powell SN; Poirier JT; Rudin CM
    Clin Cancer Res; 2017 Jan; 23(2):523-535. PubMed ID: 27440269
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Talazoparib Is a Potent Radiosensitizer in Small Cell Lung Cancer Cell Lines and Xenografts.
    Laird JH; Lok BH; Ma J; Bell A; de Stanchina E; Poirier JT; Rudin CM
    Clin Cancer Res; 2018 Oct; 24(20):5143-5152. PubMed ID: 29945991
    [No Abstract]   [Full Text] [Related]  

  • 10. Patient-derived tumor organoids with p53 mutations, and not wild-type p53, are sensitive to synergistic combination PARP inhibitor treatment.
    Madorsky Rowdo FP; Xiao G; Khramtsova GF; Nguyen J; Martini R; Stonaker B; Boateng R; Oppong JK; Adjei EK; Awuah B; Kyei I; Aitpillah FS; Adinku MO; Ankomah K; Osei-Bonsu EB; Gyan KK; Altorki NK; Cheng E; Ginter PS; Hoda S; Newman L; Elemento O; Olopade OI; Davis MB; Martin ML; Bargonetti J
    Cancer Lett; 2024 Mar; 584():216608. PubMed ID: 38199587
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification of an easy to use 3D culture model to investigate invasion and anticancer drug response in chondrosarcomas.
    Lhuissier E; Bazille C; Aury-Landas J; Girard N; Pontin J; Boittin M; Boumediene K; Baugé C
    BMC Cancer; 2017 Jul; 17(1):490. PubMed ID: 28720081
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cancer stem cells as a therapeutic target in 3D tumor models of human chondrosarcoma: An encouraging future for proline rich polypeptide‑1.
    Granger CJ; Hoyt AK; Moran A; Becker B; Sedani A; Saigh S; Conway SA; Brown J; Galoian K
    Mol Med Rep; 2020 Nov; 22(5):3747-3758. PubMed ID: 32901865
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A phase I trial of talazoparib and irinotecan with and without temozolomide in children and young adults with recurrent or refractory solid malignancies.
    Federico SM; Pappo AS; Sahr N; Sykes A; Campagne O; Stewart CF; Clay MR; Bahrami A; McCarville MB; Kaste SC; Santana VM; Helmig S; Gartrell J; Shelat A; Brennan RC; Hawkins D; Godwin K; Bishop MW; Furman WL; Stewart E
    Eur J Cancer; 2020 Sep; 137():204-213. PubMed ID: 32795876
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An orthotopic mouse model for chondrosarcoma of bone provides an in vivo tool for drug testing.
    van Oosterwijk JG; Plass JR; Meijer D; Que I; Karperien M; Bovée JV
    Virchows Arch; 2015 Jan; 466(1):101-9. PubMed ID: 25331842
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An Effective Epigenetic-PARP Inhibitor Combination Therapy for Breast and Ovarian Cancers Independent of BRCA Mutations.
    Pulliam N; Fang F; Ozes AR; Tang J; Adewuyi A; Keer H; Lyons J; Baylin SB; Matei D; Nakshatri H; Rassool FV; Miller KD; Nephew KP
    Clin Cancer Res; 2018 Jul; 24(13):3163-3175. PubMed ID: 29615458
    [No Abstract]   [Full Text] [Related]  

  • 16. Restricted Delivery of Talazoparib Across the Blood-Brain Barrier Limits the Sensitizing Effects of PARP Inhibition on Temozolomide Therapy in Glioblastoma.
    Kizilbash SH; Gupta SK; Chang K; Kawashima R; Parrish KE; Carlson BL; Bakken KK; Mladek AC; Schroeder MA; Decker PA; Kitange GJ; Shen Y; Feng Y; Protter AA; Elmquist WF; Sarkaria JN
    Mol Cancer Ther; 2017 Dec; 16(12):2735-2746. PubMed ID: 28947502
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anticancer chemosensitization and radiosensitization by the novel poly(ADP-ribose) polymerase-1 inhibitor AG14361.
    Calabrese CR; Almassy R; Barton S; Batey MA; Calvert AH; Canan-Koch S; Durkacz BW; Hostomsky Z; Kumpf RA; Kyle S; Li J; Maegley K; Newell DR; Notarianni E; Stratford IJ; Skalitzky D; Thomas HD; Wang LZ; Webber SE; Williams KJ; Curtin NJ
    J Natl Cancer Inst; 2004 Jan; 96(1):56-67. PubMed ID: 14709739
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparative Analyses of Poly(ADP-Ribose) Polymerase Inhibitors.
    Guha M; Sobol Z; Martin M; Hemkens M; Sung T; Rubitski E; Spellman R; Finkelstein M; Khan N; Hu W
    Int J Toxicol; 2022 Dec; 41(6):442-454. PubMed ID: 35989659
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase 1/2 trial of talazoparib in combination with temozolomide in children and adolescents with refractory/recurrent solid tumors including Ewing sarcoma: A Children's Oncology Group Phase 1 Consortium study (ADVL1411).
    Schafer ES; Rau RE; Berg SL; Liu X; Minard CG; Bishop AJR; Romero JC; Hicks MJ; Nelson MD; Voss S; Reid JM; Fox E; Weigel BJ; Blaney SM
    Pediatr Blood Cancer; 2020 Feb; 67(2):e28073. PubMed ID: 31724813
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Selective inhibition of mutant IDH1 by DS-1001b ameliorates aberrant histone modifications and impairs tumor activity in chondrosarcoma.
    Nakagawa M; Nakatani F; Matsunaga H; Seki T; Endo M; Ogawara Y; Machida Y; Katsumoto T; Yamagata K; Hattori A; Fujita S; Aikawa Y; Ishikawa T; Soga T; Kawai A; Chuman H; Yokoyama N; Fukushima S; Yahiro K; Kimura A; Shimada E; Hirose T; Fujiwara T; Setsu N; Matsumoto Y; Iwamoto Y; Nakashima Y; Kitabayashi I
    Oncogene; 2019 Oct; 38(42):6835-6849. PubMed ID: 31406254
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.